<DOC>
	<DOCNO>NCT02191332</DOCNO>
	<brief_summary>Observational study collect data maintain anti-retroviral activity ( quantitative HIV RNA determination ) immunological activity ( CD4 cell ) despite switch protease inhibitor nonnucleoside reverse transcriptase inhibitor ( NNRTI ) ( Viramune® ) .</brief_summary>
	<brief_title>Observational Study Patients With HIV Infection Type 1 After Switching Viramune®-Containing Therapy Regimen</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>Adult male female patient HIV type 1 infection Counterindications accord summary product characteristic ( SPC ) Viramune tablets No person 18 Pregnancy breastfeeding Use oral contraceptive Use drug affect CYP450 3A metabolism</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>